EUVIMEDObjevte EUVIMED
Crossref

Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity

Max J Bedding, Charlotte Franck, Jason Johansen-Leete, Anupriya Aggarwal, Joshua W C Maxwell, Karishma Patel iD, Paige M E Hawkins, Jason K K Low iD, Rezwan Siddiquee, Hakimeh Moghaddas Sani, Daniel J Ford, Stuart Turville and 4 more

ACS Chemical Biology · 2024

DOI: 10.1021/acschembio.3c00568 ↗

At a glance

Journal article in ACS Chemical Biology, 2024. Written by Max J Bedding and 15 co-authors. Institution: School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia. Major MEDLINE topics: SARS-CoV-2, COVID-19. Cited 15 times so far (Crossref); 51 references. Funded by: National Health and Medical Research Council, Australian Research Council, New South Wales COVID-19 Research Grant.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The development of effective antiviral compounds is essential for mitigating the effects of the COVID-19 pandemic. Entry of SARS-CoV-2 virions into host cells is mediated by the interaction between the viral spike (S) protein and membrane-bound angiotensin-converting enzyme 2 (ACE2) on the surface of epithelial cells. Inhibition of this viral protein-host protein interaction is an attractive avenue for the development of antiviral molecules with numerous spike-binding molecules generated to date. Herein, we describe an alternative approach to inhibit the spike-ACE2 interaction by targeting the spike-binding interface of human ACE2 via mRNA display. Two consecutive display selections were performed to direct cyclic peptide ligand binding toward the spike binding interface of ACE2. Through this process, potent cyclic peptide binders of human ACE2 (with affinities in the picomolar to nanomolar range) were identified, two of which neutralized SARS-CoV-2 entry. This work demonstrates the potential of targeting ACE2 for the generation of anti-SARS-CoV-2 therapeutics as well as broad spectrum antivirals for the treatment of SARS-like betacoronavirus infection.

Subjects

MeSH terms (MEDLINE)

SARS-CoV-2COVID-19HumansAngiotensin-Converting Enzyme 2Peptides, CyclicPandemicsLigandsProtein BindingPeptidyl-Dipeptidase AAntiviral Agents

Substances

Angiotensin-Converting Enzyme 2Peptides, CyclicLigandsPeptidyl-Dipeptidase AAntiviral Agents

Authors and institutions

  • School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia.
  • Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science, The University of Sydney, Sydney, New South Wales 2006, Australia.
  • School of Life and Environmental Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.
  • Kirby Institute, Sydney, New South Wales 2052, Australia.
  • Sydney Analytical Core Research Facility, The University of Sydney, Sydney, New South Wales 2006, Australia.
  • School of Medical Sciences, The University of Sydney, Sydney, New South Wales 2006, Australia.

ORCID profiles: Karishma Patel, Jason K K Low, Toby Passioura, Richard J Payne

Funding

  • National Health and Medical Research Council
  • Australian Research Council
  • New South Wales COVID-19 Research Grant
  • NSW Vaccine Infection and Immunology Collaborative

Cite

APA

Bedding, M. J., Franck, C., Johansen-Leete, J., Aggarwal, A., Maxwell, J. W. C., Patel, K., Hawkins, P. M. E., Low, J. K. K., Siddiquee, R., Sani, H. M., Ford, D. J., Turville, S., Mackay, J. P., Passioura, T., Christie, M., & Payne, R. J. (2024). Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity. ACS Chemical Biology. https://doi.org/10.1021/acschembio.3c00568

Vancouver

Bedding MJ, Franck C, Johansen-Leete J, Aggarwal A, Maxwell JWC, Patel K, et al. Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity. ACS Chemical Biology. 2024. doi:10.1021/acschembio.3c00568

BibTeX
@article{Bedding2024,
  author = {Bedding, Max J and Franck, Charlotte and Johansen-Leete, Jason and Aggarwal, Anupriya and Maxwell, Joshua W C and Patel, Karishma and Hawkins, Paige M E and Low, Jason K K and Siddiquee, Rezwan and Sani, Hakimeh Moghaddas and Ford, Daniel J and Turville, Stuart and Mackay, Joel P and Passioura, Toby and Christie, Mary and Payne, Richard J},
  title = {Discovery of High Affinity Cyclic Peptide Ligands for Human ACE2 with SARS-CoV-2 Entry Inhibitory Activity},
  journal = {ACS Chemical Biology},
  year = {2024},
  doi = {10.1021/acschembio.3c00568}
}
Start for free →